Viridian Therapeutics, Inc./DE Proceeds from Issuance of Warrants
Viridian Therapeutics, Inc./DE (VRDN) reported Proceeds from Issuance of Warrants of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfWarrants · last filed 2026-08-06
- Viridian Therapeutics, Inc./DE proceeds from issuance of warrants for the quarter ending 2026-06-30 was $0.00.
- Viridian Therapeutics, Inc./DE proceeds from issuance of warrants for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Viridian Therapeutics, Inc./DE proceeds from issuance of warrants for the quarter ending 2025-12-31 was $0.00.
- Viridian Therapeutics, Inc./DE proceeds from issuance of warrants for the quarter ending 2025-09-30 was $0.00.
- Viridian Therapeutics, Inc./DE proceeds from issuance of warrants for fiscal 2025 was $1.62M.
- Viridian Therapeutics, Inc./DE proceeds from issuance of warrants for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Viridian Therapeutics, Inc./DE proceeds from issuance of warrants for fiscal 2023 was $1.88M, a 101.18% increase from fiscal 2022.
- Viridian Therapeutics, Inc./DE proceeds from issuance of warrants for fiscal 2022 was $935.00K, a 27.24% decline from fiscal 2021.
| Period end | Proceeds from Issuance of Warrants 3 month | Proceeds from Issuance of Warrants 3 month as first filed | Proceeds from Issuance of Warrants 6 month | Proceeds from Issuance of Warrants 9 month | Proceeds from Issuance of Warrants 12 month | Proceeds from Issuance of Warrants 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-05 | $0.00 derived: sum of 2 quarters · filed 2026-05-05 | $0.00 derived: sum of 3 quarters · filed 2026-05-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $1.62M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $1.62M 10-Q · filed 2025-11-05 | $1.62M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.62M 10-Q · filed 2026-08-06 | $1.62M derived: sum of 3 quarters · filed 2026-08-06 | $1.62M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $1.62M 10-Q · filed 2026-05-05 | $1.62M derived: sum of 2 quarters · filed 2026-05-05 | $1.62M derived: sum of 3 quarters · filed 2026-05-05 | $1.62M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $935.00K derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $935.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.88M 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $935.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.88M 10-Q · filed 2024-11-12 | $1.88M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2023-06-30 | $935.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.88M 10-Q · filed 2024-08-08 | $1.88M derived: sum of 3 quarters · filed 2025-03-03 | |||
| 2023-03-31 | $946.00K 10-Q · filed 2024-05-08 | $946.00K derived: sum of 2 quarters · filed 2025-03-03 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $935.00K 10-K · filed 2025-03-03 | ||||
| 2022-09-30 | $935.00K 10-Q · filed 2023-11-13 | |||||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-13 | |||||
| 2021-12-31 | $1.28M 10-K · filed 2022-03-11 | |||||
| 2021-06-30 | $7.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $8.53M 10-Q · filed 2021-08-12 | ||||
| 2021-03-31 | $940.00K 10-Q · filed 2022-05-13 | $1.26M 10-Q · filed 2021-05-07 | ||||
| 2020-12-31 | $0.00 10-K · filed 2022-03-11 | $25.10M 10-K · filed 2021-03-26 | ||||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $19.78M 10-Q · filed 2021-08-12 | ||||
| 2020-03-31 | $19.78M 10-Q · filed 2021-05-07 | |||||
| 2019-12-31 | $2.48M 10-K · filed 2021-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |